Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp

Hassel, JC; Berking, C; Forschner, A; Gebhardt, C; Heinzerling, L; Meier, F; Ochsenreither, S; Siveke, J; Hauschild, A; Schadendorf, D

Hassel, JC (通讯作者)，Univ Hosp Heidelberg, Dept Dermatol, Natl Ctr Tumor Dis, Neuenheimer Feld 460, D-69120 Heidelberg, Germany.

EUROPEAN JOURNAL OF CANCER, 2023; 191 ():

Abstract

Tebentafusp is a new T cell receptor bispecific fusion protein and the first approved treatment option for human leucocyte antigen-A*02:01 (HLA-A*02:0......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索